Biotricity Inc. (Biotricity) today announced its financial results for its fiscal 2022 fourth quarter and year ended March 31, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “Fiscal 2022 was a pivotal year for Biotricity as we made significant strides in our product development and commercialization strategy.
Biotricity Inc. (Biotricity) today announced that the company is expected to join the Russell Microcap® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022. Membership in the Russell Microcap® Index, which remains in place for one year, includes inclusion in the appropriate growth and value style indexes.
Biotricity Inc. (Biotricity) today provided an update for its shareholders by Chief Executive Officer Waqaas Al-Siddiq, Ph.D., that discusses recent company achievements and strategic initiatives to position the business for strong 2022 results, increasing scale and accelerating growth into 2023.
Biotricity Inc. (Biotricity) will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022.
Biotricity Inc. (Biotricity) has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2022. Biotricity was also highlighted as #1 in this year’s Medical Devices category. This year’s list honors businesses that are making the biggest impact on their industries and culture as a whole-ultimately thriving in today’s ever-changing world.
